drugset
drugset / Trial / NCT05039944

SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies

NCT05039944 ↗

Phase 2 Terminated 7 enrolled Sichuan Baili Pharmaceutical Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This multi-center, open label Phase II clinical study is performed in patients with unresectable or metastatic malignant tumors of the digestive system (colorectal cancer, gastric cancer). This study is investigating the safety and efficacy of SI-B001 at monotherapy or optimal combination dose with chemotherapy in patients.

Timeline

Start
2021-11-30
Primary completion
2022-06-06
Completion
2022-06-06

Drugs

EvaluationDrugModalityDoseRoute
Subject IZALONTAMAB Monoclonal antibody — Intravenous
Background Irinotecan Small molecule 180 mg/m2 Intravenous

Indications

colorectal cancer